 DARTMOUTH, Nova Scotia, CAMBRIDGE, Mass.BUSINESS WIREIMV Inc. Nasdaq: IMV; TSX: IMV IMV or the Company, a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, today outlined its planned 2023 milestones to advance the clinical development of its lead therapeutic, maveropepimut-S MVP-S. ... IMV Inc. Announces Update and Planned 2023 Milestones to Adv... 